DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114 was filed in this application after a decision by the Patent Trial and Appeal Board, but before the filing of a Notice of Appeal to the Court of Appeals for the Federal Circuit or the commencement of a civil action. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant’s submission filed on 11/04/2025 has been entered.
Response to Arguments
Applicant’s arguments filed 11/04/2025 have been fully considered, but are moot because Applicant has amended the claims to include a limitation that is not relied upon in the prior rejection, and the currently pending claims are rejected based on different prior art that teaches the amended limitation.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-10, 12-13, 15-21 are rejected under 35 U.S.C. 103 as being unpatentable over Robinson et al. (US 2009/0142443) and further in view of Cantrell et al. (US 2012/0037175).
Regarding claim 1, Robinson teaches a composition (e.g., chewy nougat solid candy composition; Table 2) comprising
a filler, such as gelatin (Table 2),
a lipid, including vegetable oils and fats such as soybean oil and cottonseed oil ([0039]), water (Table 2),
a flavoring agent and/or an active ingredient, including stimulants such as caffeine ([0075], Table 2).
Robinson further teaches that the fats employed in the solid candy compositions are selected based on melting characteristics suitable for solid oral compositions, including fats having melting points above about 29°C, and further discloses fats having melting points in the range of about 36°C to about 45°C ([0033]). Thus, Robinson teaches a lipid having a melting point of about 29°C or above.
Robinson discloses compositions that do not require the presence of isomalt and does not include tobacco material. The absence of these optional ingredients meets the limitation that the composition is substantially free of isomalt and substantially free of tobacco material, as the exclusion of an optional component does not impart patentable distinction.
Robinson does not explicitly teach that the lipid is present in an amount of about 20% to about 50% by weight, based on the total dry weight of the composition, as recited in claim 1.
However, Cantrell teaches solid oral compositions comprising a lipid substance having a melting point of about 36°C to about 45°C, and expressly teaches that the lipid may be present in an amount of at least about 20 percent, or at least about 30 percent, on a dry weight basis, and less than about 50 percent or 60 percent, with exemplary lipid ranges including about 20–40% by dry weight ([0016]).
Robinson expressly teaches that the amount of fat is adjustable and that any amount of fat may be contemplated to provide sufficient taste masking and desired sensory properties, with multiple fat ranges disclosed depending on formulation needs ([0104]). This teaching demonstrates that lipid amount is a result-effective variable in Robinson’s compositions.
Accordingly, it would have been obvious to one of ordinary skill in the art, at the time of the invention, to modify Robinson’s composition to include lipid in the amount taught by Cantrell, because both references are directed to solid oral compositions, and both teach that lipid amount and melting point are selected to control taste, texture, mouthfeel, and melting behavior in the oral cavity. Selecting a lipid amount within the range taught by Cantrell would have been a routine optimization of Robinson’s composition.
Regarding Claim 2:
Claim 2 depends from claim 1 and further recites that the lipid has a melting point of about 36°C to about 45°C.
As discussed above, both Robinson ([0033]) and Cantrell ([0005], [0015]) expressly teach lipids having melting points within this range for use in solid oral compositions.
Regarding Claim 3:
Claim 3 depends from claim 1 and recites that the lipid is selected from palm oil, palm kernel oil, soybean oil, cottonseed oil, and combinations thereof.
Robinson teaches soybean oil and cottonseed oil as suitable lipids ([0039]), and Cantrell teaches palm oil and palm kernel oil as suitable lipids for solid oral compositions ([0015]). The selection of a lipid from among these known vegetable oils represents an obvious choice from a finite number of identified, predictable options.
Regarding Claims 4–6:
Claim 4 recites the inclusion of lecithin, sweeteners, salts, or mixtures thereof. Robinson expressly teaches sweeteners, salts, and emulsifiers, including lecithin-type components, as optional ingredients ([0075], [0077]).
Claim 5 recites one or more alkali metal salts, including sodium chloride, sodium carbonate, and sodium bicarbonate. Robinson teaches the use of salts and buffering agents, including sodium-based salts, in the disclosed compositions ([0077]).
Claim 6 recites that the active ingredient is selected from nicotine components, nutraceuticals, botanicals, stimulants, amino acids, vitamins, cannabinoids, or combinations thereof. Robinson expressly teaches stimulants such as caffeine and other nutraceutical-type active agents for use in the disclosed compositions ([0075]).
Regarding claim 7, Robinson teaches that active ingredients for use in chewing gum and solid candy compositions include nicotine ([0086], [0087], [0090]). Robinson further discloses in Table A that nicotine may be present in an amount of about 0.0001 to about 10 percent by weight.
Claim 7 recites that the composition comprises from about 0.001 to about 10 percent by weight of a nicotine component, calculated as free base and based on the total weight of the composition. Robinson’s disclosed nicotine range overlaps and encompasses the claimed range.
It has been held that overlapping ranges are prima facie evidence of obviousness (MPEP § 2144.05). Where, as here, the prior art discloses a range that overlaps or encompasses the claimed range, it would have been obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to select a value within the disclosed range.
Further, Robinson teaches incorporating nicotine into solid oral compositions, including solid candy and chewing gum compositions, for delivery to a user ([0086]–[0090]). The claimed calculation of nicotine as free base does not impart patentable distinction, as it merely defines the manner in which the nicotine amount is expressed.
Regarding claims 8–10:
Robinson teaches a chewing gum composition comprising a filler and a lipid, water, and a flavoring agent or active ingredient (see, e.g., Table 3, ingredient 220; [0033], [0041], [0075]). Robinson further teaches that flavor agents may be absorbed onto water-soluble materials such as cellulose ([0062]), thereby disclosing the use of cellulose materials as fillers in chewing gum compositions.
Claim 8 further requires that the filler is in particulate form and comprises a cellulose material. While Robinson teaches cellulose materials as fillers, Robinson does not explicitly specify that the cellulose filler is in particulate form.
Cantrell teaches that fillers and additives for oral and smokeless tobacco compositions are conventionally provided in powdered or granulated (particulate) form, including finely divided cellulose and microcrystalline cellulose, and that such particulate cellulose materials are used as fillers, binders, and disintegration or compressibility aids in oral compositions ([0029]–[0030]). Cantrell further teaches that such additives may have defined particle sizes and are admixed with other components to form the final composition.
Accordingly, it would have been obvious to one of ordinary skill in the art, prior to the effective filing date of the claimed invention, to employ Cantrell’s known particulate cellulose fillers in the chewing gum composition of Robinson in order to provide a predictable and conventional filler form suitable for oral compositions.
Claim 9 depends from claim 8 and further recites that the cellulose material comprises microcrystalline cellulose. As noted above, Cantrell explicitly teaches the use of microcrystalline cellulose as a particulate additive in oral compositions. Selection of microcrystalline cellulose as the cellulose filler would have been a routine and predictable choice from among known cellulose materials disclosed by Cantrell, yielding no unexpected results.
Claim 10 depends from claim 9 and further recites that the filler comprises a cellulose derivative. Cantrell teaches the use of modified and derivative cellulose materials as binders and fillers in oral compositions, including chemically modified celluloses (paragraphs [0029]–[0030]). The selection of a cellulose derivative as a filler material would have been an obvious variation of the cellulose fillers disclosed by Robinson and Cantrell, representing a routine substitution of known equivalents.
Regarding claims 12-13 and 15-16, Robinson teaches a chewing gum composition (Table 3, ingredient 220) comprising a filler, a lipid having a melting point of about 29°C or above, and water ([0033]; Table 3). Robinson further teaches that fats employed in the composition may have melting points below about 60°C, and in some embodiments between about 45°C and about 55°C ([0033]).
Robinson also teaches that the chewing gum composition includes water in an amount of about 10–25% by weight (Table 3, example 220), which overlaps with the claimed requirement of at least about 15% by weight and at least about 20% by weight, based on total weight of the composition. Overlapping ranges are prima facie evidence of obviousness (MPEP § 2144.05).
Robinson further teaches the inclusion of a flavoring agent in the chewing gum composition in an amount of about 0.3–2.5% by weight (Table 3, example 220), and/or an active ingredient ([0075]).
Robinson does not explicitly disclose that the lipid is present in an amount of about 20% to about 50% by weight, as recited in amended claim 12.
However, Cantrell teaches solid oral compositions comprising a lipid having a melting point of about 36°C to about 45°C, wherein the lipid is present in an amount of at least about 20%, at least about 30%, and less than about 50–60% by dry weight of the composition ([0016]). Cantrell further teaches that lipid amount is selected to control melting behavior, mouthfeel, and oral performance of the composition.
Robinson expressly teaches that lipid amount is adjustable and that any amount of fat may be contemplated to achieve desired sensory and taste-masking properties ([0104]), demonstrating that lipid amount is a result-effective variable.
Accordingly, it would have been obvious to one of ordinary skill in the art, at the time of the invention, to modify Robinson’s chewing gum composition to include lipid in the amount taught by Cantrell in order to optimize melting behavior and mouthfeel while maintaining a solid oral product.
Regarding claim 17, Robinson teaches a component selected from lecithin, sweeteners, salts, and mixtures thereof, including high fructose syrup in an amount of about 7.0% by weight (Table 3).
Regarding claim 18, Robinson teaches that the active ingredient may be selected from nicotine components, nutraceuticals, botanicals, stimulants, amino acids, vitamins, cannabinoids, and combinations thereof ([0075]). Accordingly, claim 18 is unpatentable over Robinson.
Regarding claim 19, Claim 19 recites a composition comprising from about 0.001% to about 10% by weight of a nicotine component, calculated as free base and based on the total weight of the composition.
Robinson teaches that active ingredients for use in chewing gum and solid candy compositions include nicotine ([0086], [0087], [0090]). Robinson further discloses in Table A that nicotine may be present in an amount of about 0.0001 to about 10 percent by weight.
Robinson’s disclosed nicotine range overlaps and encompasses the claimed range.
It has been held that overlapping ranges are prima facie evidence of obviousness (MPEP § 2144.05). Where, as here, the prior art discloses a range that overlaps or encompasses the claimed range, it would have been obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to select a value within the disclosed range.
Further, Robinson teaches incorporating nicotine into solid oral compositions, including solid candy and chewing gum compositions, for delivery to a user ([0086]–[0090]). The claimed calculation of nicotine as free base does not impart patentable distinction, as it merely defines the manner in which the nicotine amount is expressed.
Regarding claim 20, Claim 20 recites a composition comprising, by dry weight:
about 10–70% filler,
about 15–60% water,
about 0.1–5% alkali metal salts, and
about 0.001–10% active ingredient selected from nicotine components, nutraceuticals, botanicals, stimulants, amino acids, vitamins, cannabinoids, or combinations thereof.
Robinson teaches a composition comprising:
a filler present in an amount from about 15% to about 40%, and more specifically from about 20% to about 30% by weight of the gum base ([0041]);
water present in an amount of about 10–25% (Table 3, example 220);
alkali metal salts, including sodium chloride in an amount of about 0.01–1% (Table A); and
an active ingredient, including stimulants such as caffeine or nicotine, in an amount of about 0.0001–10% (Table A).
Each of Robinson’s disclosed component ranges overlaps or falls within the claimed ranges. It has been held that overlapping ranges are prima facie evidence of obviousness (see MPEP § 2144.05). Robinson’s disclosure therefore renders the selection of the claimed ranges an obvious matter of routine optimization.
Accordingly, it would have been obvious to one of ordinary skill in the art, prior to the effective filing date of the claimed invention, to arrive at the composition of claim 20 based on Robinson’s teachings.
Regarding claim 21:
Claim 21 recites that the filler is present in an amount of at least about 20% by weight, based on the total dry weight of the composition.
Although Robinson does not explicitly state the filler amount as a percentage of total dry weight of the composition, Robinson teaches that bulking agents serving as fillers may be present in an amount from about 15% to about 40%, and more specifically from about 20% to about 30% by weight of the gum base ([0041]).
Given that the gum base constitutes a substantial portion of the overall composition, Robinson’s disclosure necessarily encompasses filler levels of at least about 20% by weight when considered on a dry-weight basis.
Furthermore, it would have been obvious to one of ordinary skill in the art to select a filler amount of at least about 20% in order to control size, expansion, texture, and structural integrity of the composition, as taught by Robinson ([0041]).
Claim 11 is rejected under 35 U.S.C. § 103 as being unpatentable over Robinson (US 2009/0142443 A1) in view of Cantrell (US 2012/0037175 A1) and further in view of Duggins et al. (US 2013/0209540 A1).
Regarding claim 11, Robinson teaches a composition comprising a filler that includes a cellulose material, wherein flavor agents and/or active ingredients may be absorbed onto water-soluble materials such as cellulose for incorporation into oral compositions ([0062]).
Cantrell further teaches that fillers and additives used in oral compositions are preferably provided in powdered or particulate form, and that such fillers include finely divided cellulose and microcrystalline cellulose used as disintegration aids and carriers for active ingredients ([0029]–[0031]).
However, Robinson and Cantrell do not explicitly teach that the cellulose derivative is hydroxypropylcellulose.
Duggins remedies this deficiency by expressly teaching hydroxypropylcellulose as a suitable cellulose derivative, binder, and excipient for oral and pharmaceutical compositions ([0044]), thereby rendering obvious the selection of hydroxypropylcellulose as the cellulose derivative in the composition of Robinson, as modified by Cantrell.
It would have been obvious to one of ordinary skill in the art at the time of the invention to select hydroxypropylcellulose as the cellulose derivative in the composition of Robinson, as modified by Cantrell, in view of Duggins’ express teaching that hydroxypropylcellulose is a known and suitable cellulose derivative for the same intended purpose. Such a substitution represents a predictable use of a known equivalent material to obtain expected results (See MPEP § 2143I (B)).
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claim 1 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of copending Application No. 17836794 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the copending application explicitly teaches a composition comprising microcrystalline cellulose as a filler, a lipid component, water, and one or more active ingredients, which corresponds to the same compositional framework recited in claim 1 of the instant application.
Further, the lipid amounts recited in the copending application overlap with the lipid amount range recited in claim 1 of the instant application, such that the differences between the claims amount to an obvious variation in concentration within overlapping ranges of the same components. Accordingly, the claims define patentably indistinct subject matter.
Claim 2 of the instant application is the same as claim 2.
Claim 3 of the instant application is the same as claim 3.
Claim 4-7 and 9 of the instant application is render obvious by claim 1.
Claim 10-11 of the instant application is the same as claim 10-11.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JENNIFER KESSIE whose telephone number is (571)272-7739. The examiner can normally be reached on Monday - Thursday 7:00am - 5:00pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael H Wilson can be reached on (571) 270-3882. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JENNIFER A KESSIE/Examiner, Art Unit 1747